We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 13, 2021

Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531
J. Clin. Oncol 2021 May 28;[EPub Ahead of Print], JA Pollard, E Guest, TA Alonzo, RB Gerbing, MR Loken, LE Brodersen, EA Kolb, R Aplenc, S Meshinchi, SC Raimondi, B Hirsch, AS Gamis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading